(Q48575438)

12 February 2018

title

Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma. (English)

1 reference

12 February 2018

main subject

pancreas

0 references

phase II clinical trial

0 references

1 reference

Maeve A Lowery

1

0 references

Eileen M. O'Reilly

object named as

Eileen M O'Reilly

19

0 references

Zsofia K. Stadler

6

object named as

Zsofia K Stadler

1 reference

12 February 2018

author name string

David P Kelsen

2

1 reference

12 February 2018

Marinela Capanu

3

1 reference

12 February 2018

Sloane C Smith

4

1 reference

12 February 2018

Jonathan W Lee

5

1 reference

12 February 2018

Malcolm J Moore

7

1 reference

12 February 2018

Hedy L Kindler

8

1 reference

12 February 2018

Talia Golan

9

1 reference

12 February 2018

Amiel Segal

10

1 reference

12 February 2018

Hannah Maynard

11

1 reference

12 February 2018

Ellen Hollywood

12

1 reference

12 February 2018

MaryEllen Moynahan

13

1 reference

12 February 2018

Erin E Salo-Mullen

14

1 reference

12 February 2018

Richard Kinh Gian Do

15

1 reference

12 February 2018

Alice P Chen

16

1 reference

12 February 2018

Kenneth H Yu

17

1 reference

12 February 2018

Laura H Tang

18

1 reference

12 February 2018

publication date

7 December 2017

1 reference

12 February 2018

European Journal of Cancer

published in

1 reference

12 February 2018

volume

89

1 reference

12 February 2018

page(s)

19-26

1 reference

12 February 2018

Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma.

cites work

1 reference

12 December 2020

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

1 reference

12 December 2020

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

1 reference

12 December 2020

Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance

1 reference

12 December 2020

BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma

1 reference

12 December 2020

Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene

1 reference

12 December 2020

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

1 reference

12 December 2020

Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer

1 reference

12 December 2020

Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.

1 reference

12 December 2020

An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions

1 reference

12 December 2020

The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers

1 reference

12 December 2020

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

1 reference

12 December 2020

High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions

1 reference

12 December 2020

Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers

1 reference

12 December 2020

BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study

1 reference

12 December 2020

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation

1 reference

12 December 2020

Whole genomes redefine the mutational landscape of pancreatic cancer

1 reference

12 December 2020

Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma.

1 reference

12 December 2020

Identification of germline genetic mutations in patients with pancreatic cancer

1 reference

12 December 2020

Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action

1 reference

12 December 2020

10.1016/J.EJCA.2017.11.004

Identifiers

DOI

1 reference

12 February 2018

1 reference

12 February 2018